Summit Therapeutics Inc.

Summit Therapeutics Inc. is a biopharmaceutical oncology company dedicated to the discovery, development, and commercialization of medicinal therapies aimed at improving the quality and duration of human life and addressing serious unmet medical needs. The company's mission is to make a significant difference for patients, particularly in the field of oncology. Summit Therapeutics is headquartered in Miami, Florida, with additional offices located in Palo Alto, California; Princeton, New Jersey; Oxford, United Kingdom; and Dublin, Ireland.

The company's primary focus is on its lead pipeline product candidate, ivonescimab (also known as SMT112 in Summit's licensed territories), a novel bispecific antibody designed to target both PD-1 and VEGF. This investigational therapy is being developed for the treatment of various cancers, with a significant emphasis on non-small cell lung cancer (NSCLC) and colorectal cancer. Summit Therapeutics holds the licensing rights for ivonescimab in key regions including the United States, Canada, Europe, Japan, Latin America, the Middle East, and Africa, through a collaboration and license agreement with Akeso, Inc.

In recent developments, Summit Therapeutics has been actively advancing ivonescimab through global Phase III clinical trials. The company presented encouraging global Phase II data for ivonescimab in first-line metastatic colorectal cancer at ASCO 2026. Furthermore, the U.S. Food and Drug Administration (FDA) accepted a Biologics License Application (BLA) for ivonescimab, with a Prescription Drug User Fee Act (PDUFA) date set for November 14, 2026. Robert W. Duggan serves as the Co-Chief Executive Officer, Executive Chairman, and majority stockholder. The company recently announced a proposed public offering of common stock in June 2026, following the withdrawal of a previous $500 million offering in June 2026 due to market conditions.